Researchers identify a promising avenue for improving treatments for people with cystic fibrosis. They found that adding molecules called quorum-sensing inhibitors to current drugs not only reduces bacterial production of certain harmful residues but also restores the efficacy of existing treatments, such as Orkambi and Kalydeco, on the cells of cystic fibrosis patients. This breakthrough paves the way for new personalized therapies.